Cellcentric To Participate In Upcoming Investor Conferences

(MENAFN- Newsfile Corp) Cambridge, United Kingdom and Boston, Massachusetts--(Newsfile Corp. - August 5, 2025) - CellCentric, a privately held biotechnology company developing inobrodib, a first-in-class p300/CBP inhibitor for multiple myeloma, today announced that members of its senior management team will participate in several upcoming investor conferences.

These events provide an opportunity to engage with the investment community and highlight the company's clinical progress with inobrodib, which will be entering a potentially registration enabling study later this year.

Upcoming appearances include:

• Oppenheimer & Co.'s 2025 Biotech in the Berkshires , Berkshires, MA
  Presentation time: Tuesday, August 5, 2025, 11:51am ET

• Citi's 2025 Biopharma Back to School Conference, Boston, MA
  1x1s only: Tuesday, September 2, 2025

• 2025 Wells Fargo Healthcare Conference, Boston, MA
  Presentation time: September 3, 10:15am ET

• Cantor Global Healthcare Conference , New York, NY
  1x1s only: September 4, 2025

• Morgan Stanley Health Care Conference, New York, NY
  Presentation time: September 8, 2025, 3:20pm ET

• BofA Securities Healthcare Trailblazers Private Company Conference , Boston, MA
  1x1s only: September 17, 2025

MENAFN05082025004218003983ID1109887869